Following on from information provided to NICE by the company in April 2017 the appraisal of Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) – binimetinib [ID833] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 833
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- BMJ Evidence Centre, BMJ Group
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in April 2017 the appraisal of Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) – binimetinib [ID833] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 08 June 2018 | Note added to the project documents |
| 17 July 2017 | Note added to the project documents |
| 23 June 2017 | Suspended. Awaiting agreement |
| 08 June 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual